We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Technology-Based Blood Test Identifies Lung Cancer Earlier

By LabMedica International staff writers
Posted on 10 Jun 2024

Lung cancer stands as the most lethal cancer in the United States, as reported by the National Cancer Institute, and holds a similar status globally, according to the World Health Organization. More...

Annual screening using computed tomography (CT) scans for individuals at high risk can detect lung cancers at an early, more manageable stage, potentially reducing mortality rates. The U.S. Preventive Services Task Force advises that 15 million Americans aged between 50 and 80 who have smoked should undergo screening, yet only about 6% to 10% of those eligible actually receive yearly screenings. The low screening uptake is often due to the time commitment required for arranging and attending screenings, and concerns over the minimal radiation exposure from the scans. Now, researchers have leveraged artificial intelligence (AI) to spot patterns of DNA fragments linked to lung cancer, which has led to the development and validation of a liquid biopsy that could identify the disease earlier. This innovation may enhance the identification of those at highest risk and who could benefit most from further CT screening, potentially increasing screening rates and reducing death rates.

In the last five years, researchers at Johns Hopkins Medicine (Baltimore, MD, USA) have developed a test employing AI to analyze DNA fragment patterns indicative of lung cancer. This method capitalizes on the different ways in which DNA is organized in healthy versus cancerous cells. In healthy cells, DNA is compactly and uniformly structured, similar to a rolled-up ball of yarn. In contrast, the DNA in cancer cells tends to be more disorganized. As these cells die, their DNA fragments, which end up in the bloodstream, appear more chaotic and irregular compared to those from non-cancerous individuals. Through a prospective study, which was published in the journal Cancer Discovery on June 3, the team demonstrated their AI-driven technology's ability to identify individuals who are more likely to have lung cancer based on these DNA fragment patterns in the blood.

The study included roughly 1,000 participants, both with and without cancer, who qualified for conventional lung cancer screening with low-dose CT. Participants were recruited across 47 centers in 23 U.S. states. The research team trained their AI software using specific DNA fragment patterns from the blood samples of 576 individuals, both cancer-afflicted and healthy. They then confirmed their methodology's efficacy on a second cohort of 382 individuals, with and without cancer. Their analysis indicated that the test possesses a negative predictive value of 99.8%, suggesting that only 2 out of every 1,000 tested may be missed and have lung cancer. Simulation studies by the group suggest that if the screening rate could be increased to 50% within five years through this test, it could quadruple the detection of lung cancers and increase the detection of early-stage cancers by approximately 10%. This could potentially prevent around 14,000 cancer deaths over the same period. The researchers plan to seek approval for the test from the U.S. Food and Drug Administration for lung cancer screening and explore its application for other cancer types.

“We have a simple blood test that could be done in a doctor’s office that would tell patients whether they have potential signs of lung cancer and should get a follow-up CT scan,” said Victor E. Velculescu, M.D., Ph.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center. “The test is inexpensive and could be done at a very large scale. We believe it will make lung cancer screening more accessible and help many more people get screened. This will lead to more cancers being detected and treated early.” 

Related Links:
Johns Hopkins Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.